NEWSpublisher 2007 :: AngloChinese Investments
SEARCH NEWS
date from:
date to:
company:
search for string:
NEWS SECTIONS
COMPANY GROUPS
TOP NEWS
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS » Industry news » Contract Research Orgs back to previous page show list
VENTURE PHARM SERVICE--VPScro »05/08/2009 [Industry news]
AlphaRx, Venturepharm announce collaboration agreement

The goal of this is to enhance AlphaRxs research capabilities, expedite the development of new products as well as to expand the its product range.

 
AlphaRx, an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, has entered into a collaboration agreement with Venturepharm Group (the Venturepharm) to establish a drug development center in China Medical City, Taizhou, China that is expected to be used as a platform for the development of innovative drug products for the fast growing China pharmaceutical market. The goal of this is to enhance AlphaRxs research capabilities, expedite the development of new products as well as to expand the its product range. Under the terms of the agreement, AlphaRx will incorporate its China R D facility into Venturepharm\'s state of the art pre-clinical development complex. The R& D center comprises of a 200,000 sq. ft. chemistry center, a 200,000 sq. ft. multi-product pilot plant to support pilot scale formulation and Clinical Trial Material (CTM) manufacture of biopharmaceutical products and a 500,000 sq. ft. (Asia\'s largest) animal testing center (under construction). The in-house pharmaceutical research facilities provide specialized equipment for most aspects of drug research and development. AlphaRx will be responsible for all of its own product development costs and will in turn retain the intellectual property rights relating to any developed products. Mr Michael Lee, President of AlphaRx, said: Venturepharm provides the equipment and physical infrastructure to further establish our presence in China and reduces our start up investment costs. As AlphaRx continues to build its presence in China, this collaboration with Venturepharm marks an important step in our overall strategy to commercialize current products and to develop new therapeutics for the world fastest growing pharmaceutical market.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.